CART 38

Phase 1 Study of Lintivirally Transduced T Cells Engineered to Contain Anti-CD38 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Acute Myeloid Leukemia and Multiple Myeloma

Arms / Cohorts

EXPERIMENTAL: Cohort A Dose Level 1:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort A Dose Level -1:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort A Dose Level 2:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort A Dose Level 3:Relapsed/Refractory Acute Myeloid Leukemia (AML)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level 1:Multiple Myeloma (MM)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level -1:Multiple Myeloma (MM)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level 2:Multiple Myeloma (MM)

Accepting patients

EXPERIMENTAL: Cohort B Dose Level 3:Multiple Myeloma (MM)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.